Merck’s PhIII liver cancer study for Keytruda fails on two key endpoints, just three months after the FDA gave it the green light
In a rare setback, Merck has suffered a key Phase III failure for Keytruda that could put a crimp in its sales prospects.
The pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
